Abiopharma

🔍 Shin Ho (Executive)

Company: Yext, Inc. (YEXT)

Report Date: 2026-03-20

Detailed Transactions and Holdings:

• Acquired 14,062 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 284,572.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 23,125 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 307,697.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 20,000 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 327,697.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Acquired 3,493 shares of Common Stock (Direct)
  Date: 2026-03-20 | Code: A | equity_swap_involved: 0 | shares_owned_after: 331,190.00 | transaction_form_type: 4 | Footnotes: F2, F3
• Sold 34,180 shares of Common Stock at $4.79 per share (Direct)
  Date: 2026-03-20 | Code: F | equity_swap_involved: 0 | shares_owned_after: 297,010.00 | transaction_form_type: 4 | Footnotes: F4
• Sold 14,062 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 14,063.00 | transaction_form_type: 4 | Footnotes: F1, F5, F5
• Sold 23,125 shares of Restricted Stock Unit (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 161,875.00 | transaction_form_type: 4 | Footnotes: F1, F6, F6
• Sold 20,000 shares of Performance-Based Restricted Stock Unit (Derivative)
  Date: 2026-03-20 | Code: M | equity_swap_involved: 0 | shares_owned_after: 20,000.00 | transaction_form_type: 4 | Footnotes: F3, F2, F2

Footnotes:

• F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Yext, Inc.'s (the "Company") common stock.
• F2: A target of 40,000 performance-based RSUs ("PSUs") become eligible to vest based upon achievement of a combination of performance as measured using a measurement in growth of the Company's reported ARR and a "Rule of 40" summation of the percentage growth in the reported ARR and Adjusted EBITDA Margins over each of fiscal 2026 and fiscal 2027 (each, a "Performance Period"). 50% of the total target PSUs will be eligible to be earned in each Performance Period, and the maximum number of PSUs that may become eligible to vest in connection with achievement in excess of the target shall be no more than 250% of the target PSUs. The PSUs that become eligible to vest with respect to a Performance Period will vest on March 20 following the end of that Performance Period, subject to reporting person's continued service through that date. For the first Performance Period, 23,493 PSUs vested on March 20, 2026 based on achievement of approximately 117.46% performance for 20,000 target PSUs.
• F3: Each PSU represents a contingent right to receive one share of the Company's common stock.
• F4: Shares withheld to satisfy tax liability upon vesting of restricted stock units on March 20, 2026.
• F5: One-sixteenth of shares subject to award vested on September 20, 2022 and vests quarterly thereafter on each of December 20, March 20, June 20 and September 20 and in each case subject to the reporting person's continued service on each such date, until the award is fully vested on June 20, 2026.
• F6: One-eighth of shares subject to the award vested on March 20, 2026 and vests quarterly thereafter on each June 20, September 20, December 20, and March 20, subject to the reporting person's continued service on each such date, until the award is fully vested on December 20, 2027.